CVS Health announced earlier this week that it is taking action to combat high drug spending in a new comprehensive program aimed at helping patients save money on medications.
CVS Health announced earlier this week that it is taking action to combat high drug spending in a new comprehensive program aimed at helping patients save money on medications.
Through this initiative, CVS Health is launching a new tool called the CVS Pharmacy Rx Savings Finder. The tool will allow the company’s retail pharmacists to quickly evaluate individual prescription savings opportunities at the pharmacy counter for the first time.
The tool will show pharmacy teams whether the prescribed medication is on the patient’s formulary and if it’s the most affordable available option. Using the Rx Savings Finder, the pharmacist will also be able to identify whether the patient might be able to save money by filling a 90-day prescription rather than a 30-day prescription.
“Armed with the information available through our Rx Savings Finder, our more than 30,000 CVS pharmacists can play an important role by helping patients save money on their medications, providing advice on how and when to take them, and ultimately helping them achieve better health outcomes,” said Kevin Hourican, executive vice president of retail pharmacy at CVS Pharmacy. “We are beginning this process with our CVS Caremark [pharmacy benefit manager, PBM] members and expect to roll it out more broadly throughout the year.”
In another effort to combat high drug prices, the company’s PBM, CVS Caremark, is also offering its members preventive drug lists that itemize medications for many common chronic conditions that are available with no co-pay. CVS Caremark also provides a real-time benefits program with which, at time of prescribing, providers are able to see member-specific drug costs based on formulary, along with up to 5 of the lowest-cost, clinically appropriate alternatives.
During a pilot program, CVS found that 95% of patients asked to switch drugs to a lower-cost option when given the choice, and 85% of doctors also chose to make such a switch.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Top 5 Most-Read Biosimilar Articles of 2024
December 31st 2024The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the expense of the originator products, despite challenges like uptake disparities and safety concerns.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Top 5 Most-Read Rheumatology Articles of 2024
December 30th 2024The top 5 rheumatology biosimilar articles of 2024 highlight significant FDA approvals, including high-concentration adalimumab and tocilizumab biosimilars, along with evidence supporting the safety and efficacy of biosimilar-to-biosimilar switching.